Symbols / DBVT Stock $19.80 +2.38% DBV Technologies S.A.

Healthcare • Biotechnology • France • NCM
DBVT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Daniel Tassé
Exch · Country NCM · France
Market Cap 1.17B
Enterprise Value 4.48B
Income -146.95M
Sales 5.64M
FCF (ttm) -64.28M
Book/sh 3.58
Cash/sh 0.82
Employees —
Insider 10d —
IPO Oct 22, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -74.75
PEG —
P/S 207.92
P/B 5.53
P/C —
EV/EBITDA -31.12
EV/Sales 794.39
Quick Ratio 3.62
Current Ratio 3.67
Debt/Eq 3.87
LT Debt/Eq —
EPS (ttm) -5.25
EPS next Y -0.26
EPS Growth —
Revenue Growth 26.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-03-26
ROA -61.40%
ROE -149.83%
ROIC —
Gross Margin 100.00%
Oper. Margin -69.85%
Profit Margin 0.00%
Shs Outstand 59.18M
Shs Float 165.99M
Insider Own 0.00%
Instit Own 5.82%
Short Float 3.04%
Short Ratio 6.54
Short Interest 1.59M
52W High 26.18
vs 52W High -24.38%
52W Low 7.53
vs 52W Low 163.09%
Beta -0.20
Impl. Vol. —
Rel Volume 0.56
Avg Volume 272.82K
Volume 152.88K
Target (mean) $40.12
Tgt Median $46.81
Tgt Low $5.82
Tgt High $51.85
# Analysts 6
Recom Buy
Prev Close $19.34
Price $19.80
Change 2.38%
About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$40.12
Mean price target
2. Current target
$19.80
Latest analyst target
3. DCF / Fair value
$-19.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.80
Low
$5.82
High
$51.85
Mean
$40.12

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 main Citizens Market Outperform → Market Outperform $47
2026-03-27 reit Guggenheim Buy → Buy $51
2025-12-17 main HC Wainwright & Co. Buy → Buy $40
2025-12-17 main Cantor Fitzgerald Overweight → Overweight $48
2025-12-17 main Citizens Market Outperform → Market Outperform $45
2025-12-17 main Guggenheim Buy → Buy $51
2025-12-15 main HC Wainwright & Co. Buy → Buy $35
2025-12-15 init Cantor Fitzgerald — → Overweight $42
2025-12-03 init Guggenheim — → Buy $35
2025-10-29 main HC Wainwright & Co. Buy → Buy $20
2025-06-26 reit JMP Securities Market Outperform → Market Outperform $21
2025-05-27 main JMP Securities Market Outperform → Market Outperform $21
2025-05-05 main HC Wainwright & Co. Buy → Buy $16
2025-05-01 main JMP Securities Market Outperform → Market Outperform $15
2025-03-04 reit Citizens Capital Markets Market Outperform → Market Outperform $10
2025-01-10 reit JMP Securities Market Outperform → Market Outperform $10
2024-12-10 reit JMP Securities Market Outperform → Market Outperform $10
2024-10-24 main HC Wainwright & Co. Buy → Buy $7
2024-08-01 reit HC Wainwright & Co. Buy → Buy $5
2024-07-31 main JMP Securities Market Outperform → Market Outperform $5
News
RSS: Latest DBVT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-29 MOHIDEEN PHARIS Officer — 534 $22.96 $12,261
2025-07-29 MOHIDEEN PHARIS Officer — 464 $9.80 $4,547
2024-11-25 MOHIDEEN PHARIS Officer — 907 $0.53 $503
2024-07-29 MOHIDEEN PHARIS Officer — 1,785 $0.98 $1,749
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
147.05
+26.13%
116.59
+52.54%
76.43
-20.90%
96.63
Research And Development
116.68
+30.60%
89.34
+48.35%
60.22
-20.28%
75.54
Selling General And Administration
28.28
+18.54%
23.85
+4.73%
22.78
+29.69%
17.56
Selling And Marketing Expense
—
—
—
—
General And Administrative Expense
28.28
+18.54%
23.85
+4.73%
22.78
+29.69%
17.56
Salaries And Wages
17.24
+43.27%
12.03
-2.52%
12.34
+13.01%
10.92
Other Gand A
11.04
-6.62%
11.82
+13.30%
10.43
+57.11%
6.64
Other Operating Expenses
—
-0.01
+99.93%
-6.96
-896.57%
0.87
Total Expenses
147.05
+26.13%
116.59
+52.54%
76.43
-20.90%
96.63
Operating Income
-147.05
-26.13%
-116.59
-52.54%
-76.43
+20.90%
-96.63
Total Operating Income As Reported
-147.06
-26.13%
-116.59
-52.54%
-76.43
+20.90%
-96.63
EBITDA
-139.32
-27.77%
-109.05
-62.10%
-67.27
+19.40%
-83.47
Normalized EBITDA
-139.32
-27.77%
-109.05
-62.10%
-67.27
+19.40%
-83.47
Reconciled Depreciation
3.19
+445.30%
-0.93
+93.39%
-14.00
-206.35%
13.16
EBIT
-147.05
-26.13%
-116.59
-52.54%
-76.43
+20.90%
-96.63
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Restructuring And Mergern Acquisition
—
—
—
0.00
Net Income
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Pretax Income
-146.46
-28.62%
-113.86
-56.58%
-72.72
+24.41%
-96.20
Net Non Operating Interest Income Expense
0.60
-77.95%
2.73
-26.60%
3.71
+769.79%
0.43
Net Interest Income
0.60
-77.95%
2.73
-26.60%
3.71
+769.79%
0.43
Other Income Expense
—
—
—
—
Tax Provision
0.49
+792.73%
0.06
+685.71%
0.01
-90.00%
0.07
Tax Rate For Calcs
0.00
+0.00%
0.00
+249900.00%
0.00
-85.71%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Net Income From Continuing Operation Net Minority Interest
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Net Income From Continuing And Discontinued Operation
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Net Income Continuous Operations
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Normalized Income
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Net Income Common Stockholders
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Diluted EPS
—
-5.85
-53.95%
-3.80
+38.71%
-6.20
Basic EPS
—
-5.85
-53.95%
-3.80
+38.71%
-6.20
Basic Average Shares
—
19.47
+2.34%
19.02
+22.48%
15.53
Diluted Average Shares
—
19.47
+2.34%
19.02
+22.48%
15.53
Diluted NI Availto Com Stockholders
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Depreciation Amortization Depletion Income Statement
7.73
+2.47%
7.54
-17.64%
9.16
+9.46%
8.37
Depreciation And Amortization In Income Statement
7.73
+2.47%
7.54
-17.64%
9.16
+9.46%
8.37
Other Taxes
-5.64
-35.94%
-4.15
+52.70%
-8.77
-53.31%
-5.72
Total Other Finance Cost
-0.60
+77.95%
-2.73
+26.60%
-3.71
-769.79%
-0.43
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
233.72
+255.96%
65.66
-64.12%
182.99
-25.77%
246.52
Current Assets
212.94
+379.73%
44.39
-72.07%
158.91
-28.76%
223.07
Cash Cash Equivalents And Short Term Investments
194.17
+498.25%
32.46
-77.04%
141.37
-32.42%
209.19
Cash And Cash Equivalents
194.17
+498.25%
32.46
-77.04%
141.37
-32.42%
209.19
Cash Equivalents
67.05
0.00
-100.00%
130.84
-26.94%
179.09
Cash Financial
127.12
+291.66%
32.46
+208.22%
10.53
-65.02%
30.10
Receivables
16.15
+55.40%
10.39
-32.73%
15.45
+37.92%
11.20
Accounts Receivable
—
—
0.00
0.00
Other Receivables
1.58
-19.50%
1.96
+44.79%
1.35
-10.04%
1.50
Taxes Receivable
14.57
+72.81%
8.43
-40.17%
14.09
+45.36%
9.70
Prepaid Assets
2.63
+70.54%
1.54
-26.72%
2.10
-21.53%
2.68
Other Current Assets
—
—
-0.00
-200.00%
0.00
Total Non Current Assets
20.77
-2.33%
21.27
-11.63%
24.07
+2.67%
23.44
Net PPE
14.95
-11.09%
16.81
-6.24%
17.93
+1.81%
17.61
Gross PPE
37.82
+10.15%
34.34
-6.90%
36.88
+13.84%
32.40
Accumulated Depreciation
-22.88
-30.51%
-17.53
+7.52%
-18.95
-28.17%
-14.79
Properties
—
—
0.00
0.00
Buildings And Improvements
—
—
3.33
+3.52%
3.21
Machinery Furniture Equipment
3.53
+13.73%
3.10
-31.52%
4.53
+159.90%
1.74
Construction In Progress
1.16
-2.45%
1.19
-18.95%
1.46
-67.28%
4.47
Other Properties
33.14
+10.27%
30.05
-2.72%
30.89
+34.47%
22.97
Goodwill And Other Intangible Assets
0.02
-45.00%
0.04
-31.03%
0.06
+480.00%
0.01
Investments And Advances
5.19
+20.34%
4.31
—
1.77
Non Current Accounts Receivable
0.62
+458.56%
0.11
—
0.31
Non Current Prepaid Assets
—
—
—
1.77
Other Non Current Assets
-0.00
+0.00%
-0.00
-100.02%
6.08
+62.70%
3.74
Total Liabilities Net Minority Interest
64.95
+69.71%
38.27
-10.58%
42.80
-17.80%
52.06
Current Liabilities
58.02
+86.36%
31.14
-16.61%
37.34
+26.48%
29.52
Payables And Accrued Expenses
41.53
+86.92%
22.22
-5.55%
23.52
+61.77%
14.54
Payables
41.53
+86.92%
22.22
-5.55%
23.52
+61.77%
14.54
Accounts Payable
40.94
+85.83%
22.03
-5.45%
23.30
+61.00%
14.47
Total Tax Payable
0.59
+214.89%
0.19
-15.70%
0.22
+223.19%
0.07
Current Debt And Capital Lease Obligation
2.58
+72.33%
1.50
-26.00%
2.03
-32.99%
3.02
Current Debt
1.47
+73.52%
0.85
-4.19%
0.88
-21.93%
1.13
Other Current Borrowings
1.47
+73.52%
0.85
-4.19%
0.88
-21.93%
1.13
Current Capital Lease Obligation
1.12
+70.80%
0.65
-42.83%
1.14
-39.60%
1.89
Current Deferred Liabilities
—
—
0.00
-100.00%
2.14
Current Deferred Revenue
—
—
0.00
-100.00%
2.14
Other Current Liabilities
13.91
+87.53%
7.42
-37.08%
11.79
+20.07%
9.82
Total Non Current Liabilities Net Minority Interest
6.92
-2.97%
7.13
+30.68%
5.46
-75.78%
22.54
Long Term Debt And Capital Lease Obligation
5.41
-14.10%
6.30
+39.13%
4.53
+301.60%
1.13
Long Term Capital Lease Obligation
5.41
-14.10%
6.30
+39.13%
4.53
+301.60%
1.13
Other Non Current Liabilities
1.51
+80.67%
0.84
-10.28%
0.93
-95.64%
21.42
Stockholders Equity
168.77
+516.22%
27.39
-80.46%
140.19
-27.91%
194.45
Common Stock Equity
168.77
+516.22%
27.39
-80.46%
140.19
-27.91%
194.45
Capital Stock
26.91
+130.98%
11.65
+6.19%
10.97
+2.35%
10.72
Common Stock
26.91
+130.98%
11.65
+6.19%
10.97
+2.35%
10.72
Share Issued
235.67
+129.15%
102.85
+6.65%
96.43
+2.44%
94.14
Ordinary Shares Number
235.60
+129.67%
102.58
+6.62%
96.21
+2.36%
93.99
Treasury Shares Number
0.07
-72.02%
0.27
+19.68%
0.22
+48.86%
0.15
Additional Paid In Capital
541.25
+71.49%
315.61
-16.39%
377.47
-17.62%
458.22
Retained Earnings
-393.13
-37.28%
-286.38
-19.89%
-238.86
+7.98%
-259.58
Gains Losses Not Affecting Retained Earnings
-5.43
+55.46%
-12.19
-49.98%
-8.13
+41.09%
-13.80
Treasury Stock
0.83
-36.29%
1.31
+3.64%
1.26
+13.89%
1.11
Other Equity Adjustments
0.50
-45.08%
0.91
+21.97%
0.74
-4.99%
0.78
Total Equity Gross Minority Interest
168.77
+516.24%
27.39
-80.46%
140.19
-27.91%
194.45
Total Capitalization
168.77
+516.22%
27.39
-80.46%
140.19
-27.91%
194.45
Working Capital
154.92
+1069.02%
13.25
-89.10%
121.58
-37.19%
193.55
Invested Capital
170.24
+502.95%
28.23
-79.99%
141.07
-27.87%
195.59
Total Debt
7.99
+2.53%
7.80
+18.98%
6.55
+57.83%
4.15
Capital Lease Obligations
6.53
-6.11%
6.95
+22.59%
5.67
+87.69%
3.02
Net Tangible Assets
168.75
+517.04%
27.35
-80.48%
140.13
-27.93%
194.44
Tangible Book Value
168.75
+517.04%
27.35
-80.48%
140.13
-27.93%
194.44
Available For Sale Securities
5.19
+20.34%
4.31
—
1.77
Foreign Currency Translation Adjustments
-5.93
+54.75%
-13.10
-47.64%
-8.87
+39.16%
-14.58
Investmentin Financial Assets
5.19
+20.34%
4.31
—
1.77
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-121.18
-15.99%
-104.47
-31.16%
-79.65
-43.09%
-55.67
Cash Flow From Continuing Operating Activities
-121.18
-15.99%
-104.47
-31.16%
-79.65
-43.09%
-55.67
Net Income From Continuing Operations
-146.95
-28.99%
-113.92
-56.64%
-72.73
+24.46%
-96.27
Depreciation Amortization Depletion
3.19
+445.30%
-0.93
+93.39%
-14.00
-206.35%
13.16
Depreciation
3.19
+445.30%
-0.93
+93.39%
-14.00
-206.35%
13.16
Depreciation And Amortization
3.19
+445.30%
-0.93
+93.39%
-14.00
-206.35%
13.16
Other Non Cash Items
-0.22
-7133.33%
-0.00
-113.04%
0.02
+560.00%
-0.01
Pension And Employee Benefit Expense
—
0.00
-100.00%
0.08
-27.62%
0.10
Stock Based Compensation
5.39
+16.60%
4.62
-23.24%
6.02
+19.76%
5.03
Asset Impairment Charge
16.06
+1057.20%
1.39
—
—
Operating Gains Losses
—
—
0.08
-27.62%
0.10
Change In Working Capital
1.34
-69.29%
4.36
+357.92%
0.95
-95.73%
22.32
Change In Receivables
—
—
0.00
0.00
Changes In Account Receivables
—
—
0.00
0.00
Change In Inventory
-16.06
-1057.20%
-1.39
0.00
0.00
Change In Payables And Accrued Expense
15.78
+5702.57%
0.27
-96.77%
8.42
+143.63%
3.46
Change In Payable
15.78
+5702.57%
0.27
-96.77%
8.42
+143.63%
3.46
Change In Account Payable
15.78
+5702.57%
0.27
-96.77%
8.42
+143.63%
3.46
Change In Other Working Capital
-0.20
-141.86%
0.48
-70.82%
1.66
+173.90%
-2.25
Change In Other Current Assets
-4.70
-201.51%
4.63
+221.98%
-3.79
-118.11%
20.96
Change In Other Current Liabilities
6.52
+1681.69%
0.37
+106.86%
-5.33
-3609.21%
0.15
Investing Cash Flow
-1.37
-80.85%
-0.76
+6.31%
-0.81
-708.00%
-0.10
Cash Flow From Continuing Investing Activities
-1.37
-80.85%
-0.76
+6.31%
-0.81
-716.16%
-0.10
Net PPE Purchase And Sale
-0.53
+77.25%
-2.34
-245.35%
-0.68
+9.25%
-0.75
Purchase Of PPE
-0.53
+77.25%
-2.34
-245.35%
-0.68
+10.21%
-0.75
Sale Of PPE
—
—
0.00
-100.00%
0.01
Capital Expenditure
-0.54
+77.02%
-2.34
-245.79%
-0.68
+10.21%
-0.75
Net Investment Purchase And Sale
—
—
-0.13
-120.25%
0.65
Purchase Of Investment
—
—
-0.28
-131.71%
-0.12
Sale Of Investment
—
—
0.15
-80.00%
0.77
Net Intangibles Purchase And Sale
-0.01
-100.00%
-0.00
0.00
0.00
Purchase Of Intangibles
-0.01
-100.00%
-0.00
0.00
0.00
Net Other Investing Changes
-0.83
-152.46%
1.58
+1309.16%
-0.13
-13000.00%
-0.00
Financing Cash Flow
276.18
+46949.74%
0.59
-91.33%
6.77
-96.51%
194.12
Cash Flow From Continuing Financing Activities
276.18
+46949.74%
0.59
-91.33%
6.77
-96.51%
194.12
Net Common Stock Issuance
276.18
+46949.74%
0.59
-91.33%
6.77
-96.52%
194.59
Common Stock Payments
—
-0.05
+69.48%
-0.15
—
Repurchase Of Capital Stock
—
-0.05
+69.48%
-0.15
—
Net Other Financing Charges
—
—
—
-0.47
Changes In Cash
153.63
+246.81%
-104.64
-42.00%
-73.69
-153.26%
138.35
Effect Of Exchange Rate Changes
8.08
+289.32%
-4.27
-172.75%
5.87
+190.81%
-6.46
Beginning Cash Position
32.46
-77.04%
141.37
-32.42%
209.19
+170.62%
77.30
End Cash Position
194.17
+498.25%
32.46
-77.04%
141.37
-32.42%
209.19
Free Cash Flow
-121.72
-13.95%
-106.81
-32.97%
-80.33
-42.38%
-56.42
Common Stock Issuance
276.18
+43461.83%
0.63
-90.84%
6.92
-96.44%
194.59
Issuance Of Capital Stock
276.18
+43461.83%
0.63
-90.84%
6.92
-96.44%
194.59
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category